Emerging Infectious Disease ISSN: 1080-6059

Serologic Status for Pandemic (H1N1) 2009 Virus, Taiwan

Daniel Tsung-Ning Huang¹, Pei-Lan Shao¹, Kuo-Chin Huang, Chun-Yi Lu, Jen-Ren Wang, Shin-Ru Shih, Hsin Chi, Mei-Ru Lai, Chin-Yun Lee, Luan-Yin Chang, and Li-Min Huang

Author affiliations: Author affiliations: Mackay Memorial Hospital, Taipei, Taiwan (D.T.-N. Huang, H. Chi); National Taiwan University Hospital, Taipei (P.-L. Shao, K.-C. Huang, C.-Y. Lu, M.-R. Lai, C.-Y. Lee, L.-Y. Chang, L.-M. Huang); National Cheng Kung University, Tainan, Taiwan (J.-R. Wang); Chang-Gung Memorial Hospital, Taipei (S.-R. Shih); National Taiwan University, Taipei (L.-M. Huang)

Main Article

Figure

Seroprotection rates determined by hemagglutination inhibition (HI) assay (white bars) or microneutralization (MN) assay (gray bars) and geometric mean titer (GMT) of antibodies against pandemic (H1N1) 2009 virus in each 10-year age cohort, Taiwan, 2007–2008.

Figure. Seroprotection rates determined by hemagglutination inhibition (HI) assay (white bars) or microneutralization (MN) assay (gray bars) and geometric mean titer (GMT) of antibodies against pandemic (H1N1) 2009 virus in each 10-year age cohort, Taiwan, 2007–2008.

Main Article

¹These authors contributed equally to this article.

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.